Eli Lilly Company Insiders

LLY Stock  USD 777.96  0.22  0.03%   
Slightly above 58% of Eli Lilly's corporate insiders are selling. The analysis of insiders' sentiment of trading Eli Lilly And stock suggests that many insiders are alarmed at this time. Eli Lilly employs about 43 K people. The company is managed by 61 executives with a total tenure of roughly 487 years, averaging almost 7.0 years of service per executive, having 704.92 employees per reported executive.
John Lechleiter  Chairman
Chairman, CEO and Pres
Alfonso Zulueta  President
Senior Vice President and President - Emerging Markets business

Eli Lilly's Insider Buying Vs Selling

42

 
Selling
 
Buying

Latest Trades

2024-01-31Lilly Endowment IncDisposed 78573 @ 648.07View
2024-01-29Lilly Endowment IncDisposed 54032 @ 645.07View
2024-01-16Lilly Endowment IncDisposed 1180 @ 645.6View
2024-01-11Lilly Endowment IncDisposed 12344 @ 634.13View
2024-01-09Lilly Endowment IncDisposed 34538 @ 631.81View
2024-01-04Lilly Endowment IncDisposed 14388 @ 630.28View
2024-01-03Tommy TubervilleDisposed @ 617.63
2023-12-28Jared MoskowitzAcquired @ 581.28
2023-12-14Sheldon WhitehouseAcquired @ 573.69
2023-12-04John R. CurtisDisposed @ 585.56
2023-11-16Josh GottheimerAcquired @ 588.75
2023-11-13Josh GottheimerAcquired @ 613.17
2023-11-06Donald A ZakrowskiDisposed 670 @ 571.1View
2023-10-24Greg StantonDisposed @ 592.43
2023-10-11Lilly Endowment IncDisposed 215000 @ 605.44View
2023-10-03Markwayne MullinAcquired @ 525.1
2023-09-26Greg StantonAcquired @ 549.96
2023-09-21Josh GottheimerAcquired @ 550.13
2023-09-20Sheldon WhitehouseAcquired @ 569.62
Monitoring Eli Lilly's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.

Acquired vs Disposed

Filed vs Not Filed

Insider sentiment refers to the collective sentiment or feeling of Eli Lilly's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Eli Lilly And. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Eli Lilly's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly And. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Eli Lilly's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Eli Lilly's future performance. Based on our forecasts, it is anticipated that Eli will maintain a workforce of slightly above 43000 employees by April 2024.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Eli Lilly's latest congressional trading

Congressional trading in companies like Eli Lilly And, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Eli Lilly by those in governmental positions are based on the same information available to the general public.
2024-02-08Representative Josh GottheimerDisposed Under $15KVerify
2023-12-14Senator Sheldon WhitehouseAcquired Under $15KVerify
2023-12-04Representative John CurtisDisposed Under $15KVerify
2023-10-24Representative Greg StantonDisposed Under $15KVerify
2023-03-07Representative Daniel GoldmanAcquired Under $15KVerify
2022-11-28Representative Van TaylorDisposed $1,000,001 - $5,000,000Verify
2022-08-04Representative Bob GibbsDisposed Under $15KVerify
2022-07-15Representative Kathy ManningAcquired Under $15KVerify
2022-03-08Representative Dan NewhouseAcquired Under $15KVerify
2022-01-14Senator Tommy TubervilleAcquired $15K to $50KVerify
2021-03-05Representative Michael T. McCaulDisposed $250K to $500KVerify
2021-02-05Representative Kurt SchraderAcquired Under $15KVerify
2020-04-16Senator David A Perdue , JrAcquired Under $15KVerify
2020-04-16Senator David PerdueAcquired Under $15KVerify
2020-04-07Senator Kelly LoefflerAcquired Under $15KVerify
2020-03-26Representative Steve CohenDisposed Under $15KVerify
2020-02-20Representative Mikie SherrillDisposed Under $15KVerify
2019-10-17Representative Thomas SuozziDisposed Under $15KVerify
2019-02-28Representative Alan S. LowenthalAcquired Under $15KVerify
2018-08-30Representative Zoe LofgrenDisposed Under $15KVerify

Eli Lilly Management Team Effectiveness

The company has Return on Asset of 0.1188 % which means that on every $100 spent on assets, it made $0.1188 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.4844 %, implying that it generated $0.4844 on every 100 dollars invested. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities. Return On Assets is likely to rise to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.25 in 2024. At this time, Eli Lilly's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 40.2 B in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 2.9 B in 2024.
Common Stock Shares Outstanding is likely to drop to about 868.4 M in 2024. Net Income Applicable To Common Shares is likely to drop to about 4 B in 2024

Eli Lilly Workforce Comparison

Eli Lilly And is currently regarded as number one stock in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 2.94 Million. Eli Lilly claims roughly 43,000 in number of employees contributing just under 2% to equities under Health Care industry.

Eli Lilly Profit Margins

The company has Net Profit Margin of 0.15 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.34 %, which entails that for every 100 dollars of revenue, it generated $0.34 of operating income.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.620.8073
Way Down
Pretty Stable
Operating Profit Margin0.280.3026
Significantly Down
Slightly volatile
Pretax Profit Margin0.250.1921
Significantly Up
Very volatile

Eli Lilly Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eli Lilly insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eli Lilly's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Eli Lilly insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-03-01
0.5
50
100
 215,448 
 960,188 
2023-12-01
2.8
28
10
 8,444 
 237,639 
2023-09-01
0.2
18
90
 349.00 
 1,057,853 
2023-06-01
0.25
20
80
 6,738 
 1,534,042 
2023-03-01
1.6571
58
35
 305,462 
 568,377 
2022-12-01
0.6739
31
46
 29,999,033 
 826,106 
2022-09-01
0.6818
15
22
 1,145 
 389,429 
2022-06-01
0.2432
18
74
 8,156 
 2,004,859 
2022-03-01
0.902
46
51
 368,717 
 1,486,308 
2021-12-01
0.7857
22
28
 11,953 
 784,800 
2021-09-01
0.2432
9
37
 277.00 
 1,150,592 
2021-06-01
0.3333
12
36
 21,861 
 905,898 
2021-03-01
1.1892
44
37
 34,902,818 
 1,073,169 
2020-12-01
3.2
16
5
 27,737 
 11,429 
2020-09-01
0.3125
5
16
 8,750 
 474,970 
2020-06-01
0.0638
3
47
 38.00 
 1,771,775 
2020-03-01
0.9189
34
37
 41,403,910 
 1,495,503 
2019-12-01
0.8966
26
29
 32,949 
 2,069,427 
2019-09-01
1.2727
14
11
 3,637 
 266,426 
2019-06-01
1.6667
15
9
 15,221 
 67,112 
2019-03-01
1.4737
56
38
 584,626 
 1,405,426 
2018-12-01
0.7097
22
31
 31,101 
 1,454,683 
2018-09-01
0.3824
13
34
 9,148 
 2,659,746 
2018-06-01
0.56
14
25
 64,807 
 1,212,526 
2018-03-01
1.6563
53
32
 494,550 
 316,850 
2017-12-01
1.375
22
16
 77,327 
 507,830 
2017-09-01
1.0
7
7
 8,018 
 785,000 
2017-06-01
0.6667
8
12
 415,314 
 879,635 
2017-03-01
1.25
30
24
 668,132 
 1,084,680 
2016-12-01
2.0
16
8
 29,513 
 228,052 
2016-09-01
0.8
8
10
 15,136 
 897,358 
2016-06-01
0.3077
4
13
 1,339 
 1,207,680 
2016-03-01
1.5
30
20
 500,130 
 203,419 
2015-12-01
0.5909
13
22
 100,712 
 1,690,126 
2015-06-01
0.15
3
20
 127,108 
 1,686,579 
2015-03-01
0.8485
28
33
 688,717 
 847,772 
2014-12-01
0.6364
14
22
 175,038 
 1,635,403 
2014-09-01
0.2727
6
22
 60,347 
 1,246,453 
2014-06-01
0.1176
2
17
 17,157 
 2,082,530 
2014-03-01
1.5789
30
19
 863,010 
 326,988 
2013-12-01
2.75
11
4
 28,205 
 5,962 
2013-06-01
0.2222
2
9
 20,000 
 57,833 
2013-03-01
1.2174
28
23
 888,564 
 571,211 
2012-12-01
1.375
11
8
 40,268 
 45,414 
2012-03-01
1.7059
29
17
 971,937 
 668,281 
2011-12-01
2.4
12
5
 41,447 
 35,107 
2011-09-01
1.6667
5
3
 4,200 
 9,618 
2011-06-01
0.5556
5
9
 8,354 
 34,101 
2011-03-01
0.8333
20
24
 914,445 
 658,293 
2010-12-01
3.5
7
2
 29,309 
 2,489 
2010-03-01
0.7037
19
27
 889,577 
 357,814 
2009-12-01
4.6667
14
3
 34,207 
 2,673 
2009-09-01
8.0
8
1
 7,142 
 187.00 
2009-06-01
0.75
3
4
 657.00 
 30,463 
2009-03-01
0.8462
11
13
 296,407 
 196,494 
2008-12-01
10.0
10
1
 32,452 
 0.00 
2008-09-01
0.0019
3
1604
 466.00 
 1,835,000 
2008-03-01
0.5556
15
27
 259,272 
 231,713 
2007-12-01
13.0
13
1
 20,632 
 1,626 
2007-09-01
0.0422
7
166
 5,711 
 365,596 
2007-06-01
0.0111
8
720
 100,584 
 2,632,780 
2007-03-01
0.6957
16
23
 198,146 
 292,245 
2006-12-01
0.0237
14
591
 27,454 
 1,358,650 
2006-09-01
0.0152
12
790
 21,922 
 2,153,422 
2006-06-01
0.0056
6
1068
 705.00 
 2,987,068 
2006-03-01
0.0734
24
327
 608,381 
 1,324,359 
2005-12-01
1.2667
19
15
 128,874 
 263,933 
2005-09-01
0.0147
16
1089
 54,709 
 2,690,655 
2005-06-01
0.0256
12
468
 137,093 
 1,097,238 
2005-03-01
1.2222
22
18
 501,531 
 241,686 
2004-12-01
4.6667
14
3
 31,608 
 24,500 
2004-09-01
0.0154
8
518
 46,788 
 884,814 
2004-06-01
0.0101
8
795
 4,030 
 1,720,872 
2004-03-01
0.1301
19
146
 616,904 
 645,667 
2003-12-01
0.1579
12
76
 4,541 
 165,100 
2003-09-01
0.005
6
1210
 348.21 
 2,615,255 
2003-06-01
0.5
1
2
 1,000.00 
 1,863 

Eli Lilly Notable Stakeholders

An Eli Lilly stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Eli Lilly often face trade-offs trying to please all of them. Eli Lilly's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Eli Lilly's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Jacob NaardenSenior Vice President, Chief Executive Officer - Loxo Oncology at Lilly, President - Lilly OncologyProfile
John LechleiterChairman, CEO and PresProfile
Johna NortonSenior Vice President - Global QualityProfile
Alfonso ZuluetaSenior Vice President and President - Emerging Markets businessProfile
Anne WhiteSenior Vice President and Presidentident - Lilly OncologyProfile
Melissa BarnesSenior Vice President - Enterprise Risk Management and Chief Ethics and Compliance OfficerProfile
Patrik JonssonSenior Vice President, Chief Customer Officer, President - Lilly Immunology, Lilly USAProfile
Enrique ConternoSenior Vice President and President - Lilly Diabetes and President - Lilly USAProfile
Myles ONeillSenior Vice President and President - Manufacturing OperationsProfile
David RicksSenior Vice President and Presidentident - Lilly Bio-MedicinesProfile
Daniel SkovronskySenior Vice President, Chief Scientific and Medical Officer, President - Lilly Research LaboratoriesProfile
Joshua SmileyChief Financial Officer, Senior Vice PresidentProfile
Anat HakimSenior Vice President, General Counsel, SecretaryProfile
Fionnuala WalshSenior Vice President - Global QualityProfile
Anat AshkenaziChief Financial Officer, Senior Vice PresidentProfile
Jeffrey SimmonsSenior Vice President and President - Elanco Animal HealthProfile
Leigh PuseySenior Vice President - Corporate Affairs and CommunicationsProfile
Darren CarrollSenior Vice President - Corporate Business DevelopmentProfile
Christi ShawSenior Vice President and President - Lilly Bio-MedicinesProfile
Barton PetersonSenior Vice President - Corporate Affairs and CommunicationsProfile
Michael HarringtonExecutive Vice President, General CounselProfile
Maria CrowePresident - Manufacturing OperationsProfile
Jan LundbergExecutive VP of Science and Technology and President of Lilly Research LaboratoriesProfile
Aarti ShahSenior Vice President - Chief Information and Digital OfficerProfile
Susan MahonySenior Vice President and President - Lilly OncologyProfile
Stephen FrySenior Vice President - Human Resources and DiversityProfile
Derica RiceCFO, Executive VP of Global Services, Member of Operations Committee and Member of Policy and Strategy CommitteeProfile
Ralph AlvarezIndependent DirectorProfile
Jamere JacksonIndependent DirectorProfile
Juan LucianoLead Independent DirectorProfile
Karen WalkerIndependent DirectorProfile
Raul AlvarezIndependent DirectorProfile
Marschall RungeIndependent DirectorProfile
Carolyn BertozziIndependent DirectorProfile
Erik FyrwaldIndependent DirectorProfile
Franklyn PrendergastIndependent DirectorProfile
Ellen MarramLead Independent DirectorProfile
Kathi SeifertIndependent DirectorProfile
Gabrielle SulzbergerIndependent DirectorProfile
Karen HornIndependent DirectorProfile
William KaelinIndependent DirectorProfile
David HooverIndependent DirectorProfile
Jackson TaiIndependent DirectorProfile
Michael EskewIndependent DirectorProfile
Katherine BaickerIndependent DirectorProfile
Bronwen MantloDeputy VPProfile
Anat JDGeneral VPProfile
J FyrwaldIndependent DirectorProfile
Mark MDSenior DevelopmentProfile
Ilya YuffaSenior Vice President and President of Lilly Bio-MedicinesProfile
Edgardo HernandezSenior Vice President and Presidentident - Manufacturing OperationsProfile
Donald ZakrowskiChief FinanceProfile
David MDChief OfficerProfile
Eric DozierExecutive DiversityProfile
Alonzo WeemsSenior Vice President - Enterprise Risk Management, Chief Ethics and Compliance OfficerProfile
Jim GreffetHead StrategyProfile
Kimberly JohnsonIndependent DirectorProfile
Diogo RauSenior Vice President Chief Information and Digital OfficerProfile
Martin MIBSVP ProjectsProfile
Michael MasonSenior Vice President and President Lilly DiabetesProfile
Winselow TuckerSenior LoxoProfile

About Eli Lilly Management Performance

The success or failure of an entity such as Eli Lilly And often depends on how effective the management is. Eli Lilly management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Eli management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Eli management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for 2024
Return On Capital Employed 0.28  0.25 
Return On Assets 0.08  0.12 
Return On Equity 0.49  0.26 
The data published in Eli Lilly's official financial statements usually reflect Eli Lilly's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Eli Lilly And. For example, before you start analyzing numbers published by Eli accountants, it's critical to develop an understanding of what Eli Lilly's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Eli Lilly's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Eli Lilly's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Eli Lilly's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Eli Lilly And. Please utilize our Beneish M Score to check the likelihood of Eli Lilly's management manipulating its earnings.

Eli Lilly Workforce Analysis

Traditionally, organizations such as Eli Lilly use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Eli Lilly within its industry.

Eli Lilly Manpower Efficiency

Return on Eli Lilly Manpower

Revenue Per Employee793.6K
Revenue Per Executive559.4M
Net Income Per Employee121.9K
Net Income Per Executive85.9M
When determining whether Eli Lilly And offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly And. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for Eli Stock analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.13
Dividend Share
4.52
Earnings Share
5.84
Revenue Per Share
37.908
Quarterly Revenue Growth
0.281
The market value of Eli Lilly And is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.